Summary of Piracetam
Primary Information, Benefits, Effects, and Important Facts
Piracetam is the prototype for racetam supplements, which are a group of synthetic supplements intended to provide a cognitive boost.
Piracetam has a history of being used to treat cognitive impairment. According to a meta-analysis on human studies, piracetam improves general cognition when supplemented by people in a state of cognitive decline, such as the kind that comes with aging. Though piracetam may be a useful supplement for improving longevity, it offers limited benefits for healthy people.
Healthy people supplementing piracetam do experience little to no cognitive benefit. Though piracetam supplementation in healthy people is understudied, preliminary evidence suggests that piracetam is most effective for older people. Piracetam supplementation has also been found to reduce the chances of a breath-holding spell in children.
Piracetam enhances cellular membrane fluidity. This mechanism explains why piracetam is able to improve cognition, particularly in elderly people.
Piracetam is as effective as aspirin when it comes to preventing blood clotting, which makes it a useful supplemental intervention after cardiovascular trauma.
Tired of all the misinformation spread by supplement companies?
Learn what works, what's a waste, and how to achieve your health goals with our free supplement mini-course.
Things To Know & Note
Piracetam is water-soluble, and does not need to be taken with food
Many studies note a high inter-individual variability
It is (anecdotally) reported to be non-stimulatory and non-sedative
How to Take Piracetam
Recommended dosage, active amounts, other details
The standard piracetam dose for children is between 40-100mg per kilogram of bodyweight. This dose is intended for the treatment of breath-holding spells, though it has also been used for children with dyslexia. The lower end of the range (40-50mg/kg) is used most often.
The standard piracetam dose for adults is between 1,200-4,800mg a day. The largest effective dose is 1,600mg, taken three times a day for a total of 4,800mg.
Need guidance?If you need something quick and easy to let you see which supplements do what to your health (and vice versa), check out our A-to-Z Supplement Reference.
If you are looking for clear directions that will save you time and money and help improve your health, then you need our Supplement Guides.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects piracetam has on your body, and how strong these effects are.
|Grade||Level of Evidence [show legend]|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Notable||Very High See all 6 studies|
|Strong||Very High See all 3 studies|
|Minor||- See study|
|Minor||Very High See 2 studies|
|-||- See study|
|-||- See study|
Studies Excluded from Consideration
Scientific Research on Piracetam
Click on any below to expand the corresponding section. Click on to collapse it.
Piracetam (known as (2-oxo-1-pyrrolidine-acetamide) is a synthetic compound of the racetam family, and shares the characteristic 5-carbon oxopyrrolidone ring structure. Piracetam was the first of the racetam family, and developed by UCB Pharma in Belgium, and is also known as Nootropyl or UCB6215. It is a nootropic compound, derived from the greek word noos (mind) and tropein (towards); ultimately meaning 'towards the mind'.
Synthetic molecule designed to enhance brain function. Piracetam is the basic 'racetam' molecule of a family of related compounds
Piracetam tends to share structural similarity to the neurotransmitter GABA, as it is a cyclical derivative; as such it retains two nitrogens in its structure with one amine bearing the two-carbon side chain that has the other nitrogen within it. The skeleton structure and computed minima via conformational analysis (PBE0/6-31G(d,p)) are depicted below; via this article.
Piracetam does not occur naturally in any food or plant source.
In youth given 1600mg Piracetam orally in a fasted state, a Cmax of 27.6+/-1.3ug/mL is reached in 0.90+/-0.15 hours and a 24 hour AUC of 145ug/min/mL is achieved.
In older individuals, the same fasted 1600mg dose yields a Cmax of 32.82+/-3.6ug/mL in a similar (0.86+/-0.14h) Tmax, but the 24 hour AUC is extended to 188ug/mL/min; this is thought to be due to a lower urinary excretion rate.
Increased brain oxygen consumption has been noted mostly during periods of insufficient neuronal oxidation following Piracetam ingestion or incubation with neurons. As these observations are indicative of glucose consumption, interactions with glucose oxidation were ingestigated and found to be increased in rats and replicated in humans following two 6g infusions of Piracetam.
Interestingly, the aforementioned study divided dementia patients into those with Alzheimer's and those without and only in the Alzheimer's group (where glucose consumption is significantly perturbed) was there a statistically significant increase of 8-10% glucose consumption, suggesting a mechanism unique to cognitively impaired persons.
Piracetam (and Leviracetam) have been found to antagonize an inhibition of glucose uptake into erythrocytes induced by hypnotic drugs (including Melatonin) which is likely related to membrane fluidity. A possible connection between membrane fluidity and glucose consumption exists, although plausible mechanisms also exist for glucose consumption being enhanced downstream of modulating ion currents and action potentials.
Overall, Piracetam increases glucose and oxygen consumption in brains which precedes cognitive improvement (as these benefits are global (not favoring certain brain regions) and more significant in cognitively impaired persons, both of which are in accordance with interventions in humans).
The exact mechanisms underlying the enhancement of glucose and oxygen consumption are currently not established
Influences on neurons may be mediated by positively modulating AMPA-gluatmate receptors, which can increase calcium influx into neurons and increase the density of AMPA receptor binding sites. This mechanism of action is similar to Aniracetam and oxiracetam and like those two, Piracetam does not significantly act on or modulate the other two glutamate receptor subtypes, NMDA and Kainate receptors, although 500mg/kg to aged mice for 2 weeks may increase the amount of NMDA receptors expressed. Increased receptor expression has been noted with acetylcholine receptors as well only in aged mice (no effect in youth), suggesting that this is a basic mechanism not unique to glutaminergic receptors.
Piracetam shows affinity for two subsets of AMPA (glutamate) receptors, Glu2 and Glu3, and may attenuate the rate of action potentials. It does not appear to directly act upon the other two glutamate receptors (Kainate and NMDA) although the ability of piracetam to possibly increase receptors in general in aged mice may influnce these two receptor classes
Piracetam was initially shown to reduce high voltage-dependent calcium influx into neurons has been found to inhibit CAV2.2 calcium channels in some peripheral and central neurons with an IC50 value of 3.4umol/L and a maximal efficacy of 94+/-2% inhibition at 2000umol/L. The effects of Piracetam were independent of a G-Protein Coupled Receptor (GPRC), were reversible, and were not occluded by noradrenaline (which had some additive benefits with Piracetam). These effects were noted in superior cervical ganglion cells (large percentage of CAV2.2 channels) and in CA1 hippocampal neurons, where Piracetam at 10umol/L reduced action potential frequency from 133+/-11% (action potential on regular neurons, with 100% resting levels) to 97+/-10%, excitatory post-synaptic potentials were reduced from 80+/-7% in control to 18+/-5% with Piracetam. These mechanisms are similar to that of Leviracetam.
The authors noted a reduction of resting membrane potential after action potential, and suggested that other ion channels could be getting modified by Piracetam.
May interact with Calcium Channels, where it attenuates excessive neuronal firing
Piracetam is initially formed via using Gamma-Amino Butyric Acid (GABA) and, after losing a molecule, assuming a cyclical shape. That being said, Piracetam does not appear to interact with GABA receptors.
No significant interactions with GABA receptors despite its origin being a GABA derivative
Piracetam can interact with phospholipid structures due to having high affinity for the polar head of the phospholipid, which may underlie changes (increases) in membrane fluidity that may act in a therapeutic manner, as it had no apparent benefit to membrane fluidity in otherwise healthy young brain slices (independent of species tested).
Membrane fluidity is lessened (rigidity promoting) in instances of oxidative and lipid peroxidative stress, where Piracetam appears to act to normalize fluidity. A normalization of mitochondrial function secondary to preserving fluidity is noted in instances of excessive oxidative stress and perturbed fluidity in the mitochondria is associated with states of cognitive decline. As Piracetam is implicated in increasing mitochondrial membrane fluidity in aged brain only and this preservation of mitochondrial membrane potential is associated with improvements in Aß1–42 levels and preserving neurite outgrowth in animals.
Appears to preserve membrane fluidity, which may be due to increasing membrane fluidity in states where fluidity is compromised. These benefits correlate better to instances of cognitive improvement in cognitive degeneration than do AMPA or Calcium channel modulation/inhibition
One study in 16 otherwise healthy subjects (3:1 male) using 400mg Piracetam taken thrice a day (1200mg total) for a period of 14 days conducted in a matched pair manner (8 given the drug in double-blind manner) noted that while no differences existed at baseline or 7 days in, that 14 days in the Piracetam group was significantly better at a test of backwords word recall; suggesting improvements to short-term working memory.
One study has noted that, using non-dyslexic persons as a control to test the efficacy of Piracetam in dyslexics, that the apparently healthy controls experienced an 8.6% improvement relative to placebo on measures of verbal learning; this was seen with 4.8g Piracetam over 21 days.
One study has been conducted on 18 persons aged 50 or above but with no salient signs of cognitive decline, which noted that thrice daily doses of 1600mg (4800mg daily) was associated with general improvement in cognition on a battery of tests, with no specific subset showing a large magnitude of benefit. This study was single blind and lasted 8 weeks, and the blinding may have failed due to the majority of the subjects receiving Piracetam properly guessing so.
In young and otherwise healthy adults, some (quite weak) cognitive enhancement is apparent. These benefits are more pronounced in populations where cognitive impairment may not be present but optimal cognition is likely not present either (such as 'organic' cognitive decline associated with healthy aging)
A meta-analysis on Piracetam assessing 19 double-blind trials noted a significant benefit associated with Piracetam when it came to persons with some manner of cognitive ailment. This study built of a 1997 Cochrane Meta-Analysis that assessed 5 studies and found benefit with an Odds Ratio of 2.89 (95% CI of 1.01-8.24) barely showing statistical significance with limited studies, and noted that when assessing 19 studies that met the inclusion criteria of double-blind and parallel studies (54 in total, excluding 35 including cross-over) noted that in 1,488 persons the Odds Ratio for improvement with Piracetam over Placebo was 3.35 (95% CI of 2.70-4.17) using fixed effects model, and a similar OR and CI were noted for Mantel Haenszel and random effects model. Excluding the two most statistically influencing studies (one of which is located online) reduce the OR to 2.50 (95% CI 1.96-3.17). Numerically, this meta-analysis concluded that the amount of people reporting improvement is 112% higher (60.9% in piracetam and 32.5% in placebo) with piracetam relative to placebo and no effects on cognitive or worsening thereof is reduced 34.4-37.9% relative to placebo (magnitude of improvement not assessed due to hetergeneity of the data).
This aforemented Meta-Analysis excluded 3 double-blind trials (only one of which is located online) despite reporting benefit due to note reporting categorical data that could not be put into meta-analysis. Studies included in meta-analysis that can be located online are cited as follows.
In a self-report survey from outpatients of cerebrovascular disorders, Piracetam showed a modest memory improvement, a much greater response was seen in in vivo models of traumatic brain injury.
There appears to be sufficient evidence to indicate that an improvement in cognitive function exists in persons with degenerating cognitive function. Lots of studies not published online or otherwise just presented at symposiums, however, Piracetam may have slightly more benefit in instances of neural trauma when compared to its benefits in organic cognitive decline
One review exists on Dyslexia in particular when it comes to Piracetam where 4 double-blind crossover studies and 7 double blind studies (encompassing 591 dyslexic or learning disordered boys aged 8-13 and one study with 30 16-21 year old dyslexics) and overall tended to note improvements to verbal learning and comprehension associated with 1.2-3.3g Piracetam daily for up to 8 weeks while other non-verbal parameters measured were much less constant.
When dyslexic studients are given Piracetam and paired against otherwise healthy peers, a greater increase appears to be apparent with Dyslexic students (15% more than placebo) than with non-dyslexic counterparts (8.6% more than placebo) over a period of 21 days.
Is associated with improvements to verbal learning and performance in Dyslexics
One trial assessing the neuroprotective effects of an acute dose of Piracetam prior to open-heart surgery failed to find a benefit relative to placebo when cognition was assessed 3 days after surgery, this is in contrast to apparent neuroprotective effects on coronary bypass surgery, which has been noted previously.
One study on ischemic cerebrovascular disease in persons suffering from aphasia (impairment of language ability, in this case due to brain hypoxia) using 4.8g Piracetam daily for 6 months after stroke noted that, after assessment via the GAT, NIHSS, mRS and BI rating scales, that while there was significant improvement in regards to auditory comprehension there was no significant influence on the other measured parameters of spontaneous speech, reading fluency, reading comprehension, repetition, and naming when compared to placebo. These null results are in contrast to previous research, where 6 weeks of 4800mg Piracetam was associated with improvements in 6 languages tests whereas placebo only improved in three, and one other study assessing brain waves which suggested improvements.
Mixed evidence on the benefits of Piracetam on recovery of language function after Stroke, with either significant improvement existing or minor trends towards improvement
One study assessing the effects of 4.8g Piracetam on whether or not it could reduce Cocaine dependence found that, after 10 weeks, the Piracetam group was associated with more Cocaine use than placebo and was rated as worse than both placebo and the other tested group, Ginkgo Biloba, which had no effect.
The lone study assessing cocaine dependence has noted an increased dependency of cocaine dependence associated with Piracetam usage
Piracetam appears to have analgesic properties in response to acute inflammatory hyperalgesia at 30-300mg/kg oral intake (in rats) an hour prior to testing, with dose-dependent reductions in pain reaching up to 41% inhibition of acetic acid induced writhing. These benefits were thought to be secondary to the antiinflammatory properties of Piracetam.
There appears to be analgesic properties against acute inflammatory pain
Piracetam has been shown, via self-report, to be somewhat effective at reducing depression associated with cerebrovascular disorders. These have not been investigated in otherwise healthy persons.
Breath Holding Spells (BHSs) are periods of episodic apnea that sometimes occur in otherwise healthy children (starting at 6-28 months, usually fading by 5-9 years old), where most of the time it is benign yet causes distress to the parent of the unbreathing child (with only 21% of parents, being told it is benign, find relief); it is thought to be due to the autonomous nervous system with a relationship between symptoms and diffuse cerebral anoxia.
Piracetam is tested for alleviating BHS in children. One study of 40 children (5-60 months; average 32.5) using 50mg/kg Piracetam daily via Stimulan syrup for a period of 4 months was associated with significantly improved symptoms. While both groups had 5-5.5 attacks per month at baseline, placebo maintained at an average 4-5 attacks per month while Piracetam was assocaited with 0-1 attacks, with 72.08% symptoms reduction within one month and 83.85% symptom reduction after 4 months; 5-6 patients seemed to have a delayed response, taking two months to be affected. This study builds off previous non-blinded studies where Piracetam (50-100mg/kg daily, only 100mg/kg was used if no effect was observed at 4 weeks) over 3-6 months (with supplemental Iron is too low, as that is tied to pathology; no differences between iron treated and untreated groups) abolished BHS in 81% of children, attenuated attacks in 9%, and had no significant effect on 10%. A much earlier double-blind study with 40mg/kg (divided into two doses daily) Piracetam where 92.3% of children reported benefit; compared to 29.7% of placebo.
These studies do not seem to report any significant difference between cyanotic or pallid BHS symptoms, benefitting both to equal degrees. Some case studies suggest this may extend to Leviracetam, another Racetam compound. Additionally, in these studies on children, the doses (50-100mg/kg bodyweight) used for the specified durations are not associated with any observed side effects.
Piracetam appears to be highly effective and safe in the treatment of Breath Holding Spells (BHSs) in children, and has not been associated with toxic effects at the dose range of 40-100mg/kg bodyweight
A pilot study in Ataxia where 8 patients were given intravenous doses of 30-60g Piracetam daily (escalating dose) for 14 days (based off a previous case study with high dose Piracetam) noted improvements in clinician assessment of Ataxia via the International Cooperative Ataxia Rating Scale (ICARS) where score was dropped from 39.4+/-17 to 30.9+/-14.9, a 21% improvement on average. Significant improvement was seen globally and on posture/gait subscales, but not kinetic functions, speech and oculomotor disorders where it trended to improve the former two with no effect on oculomotor disorders; no side effects were reported by the patients.
At least one study existed in Schizophrenic patients (n=40) where 4.8g of Piracetam daily for 4 weeks in addition to standard antipsychotic therapy noted minor decreases in global rating of symptoms while a more significant decrease was noted in the subscales of Tardive Dyskinesia; this apparent benefit was mediated by unknown mechanisms.
Anti-platelet effects of Piracetam have been known to occur in humans for quite some time (1975) that are apparent in rats at 200mg/kg and in humans at 4.8-9.6g daily (three doses of 1.6g) with no practically significant efficacy with 1.6 or 3.2g in a day.
Mechanisms underlying these effects are somewhat elusive, and at least one study has noted that the IC50 values (concentration required to exert 50% effects) are 10-fold higher outside the body in vitro than they are achieved in vivo when measuring extracted serum.
In hyperactive disorders (acute stroke, Type II Diabetes, Raynaud's phenomenon), a normalization of platelet function occurs. One possibility is the rheological effects of Piracetam (increasing membrane fluidity) normalizing cell function, but other possibilities that have not been excluded are reducing the sensitivity of platelets to ADP or inhibition of Thromboxane A2 synthesis (a proinflammatory prostaglandin).
Appears to inhibit blood clotting at doses in the higher range for those used in cognitive enhancement (4.8g or above), with the mechanisms currently unknown
One large intervention that was comparative between Piracetam at 4.8g (1600mg thrice a day) and Aspirin (Acetylsalicyclic Acid; ASA) at 200mg thrice a day over the course of 2 years followup in persons who suffered a stroke (n=563) noted that there were no significant differneces between the two groups in regards to preventing death and stroke, but that Piracetam was significantly better tolerated (with 12.5% of persons in Piracetam reporting adverse events, and 21.8% with ASA). That being said, the apparent non-response to ASA that occurs in some persons also appears to apply to Piracetam.
4.8g daily (in three doses of 1.6g) appears to be optimal due to peak efficacy at 1-4 hours post consumption and declining efficacy 8-12 hours after consumption.
May be effective as prophylaxis after strokes to maintain blood flow, with one study suggesting no significant differences when compared to Aspirin (commonly the first choice for prophylaxis after stroke)
It is known that mediators in the inflammatory pain response (hyperalgesia) are prooxidative molecules, as inflammatory cytokines (such as TNF-α) can cause intracellular increases in prooxidants such as H2O2, peroxynitrate, and superoxide mediate the subsequent pain response. Preventing these oxidative molecules either directly (antioxidants) or indirectly via preventing the actions of inflammatory cytokines can reduce hyperalgesia.
Oral ingestion of 30-300mg/kg Piracetam to rats prior to inflammatory stimuli (carrageenin) was able to reduce myeloperoxidase (MPO) activity at 100mg/kg, and this effect was replicated with localized treatment. When looking at mechanisms, it appears that piracetam failed to reduce TNF-α levels in serum but prevented TNF-α from inducing secretion of IL-1β and MPO and reducing prooxidative changes.
Piracetam appears to prevent TNF-α from causing an inflammatory response, which underlies the pain reducing effects of Piracetam by preserving intracellular oxidant status
One study has been conducted in Acute Acoustic Trauama (AAT) with Piracetam (dose not specified) paired with steroid therapy (Prednisone at 25mg IV thrice daily) noted that the combination therapy was able to preserve hearing function in persons dependent on time of intervention; 65% of persons with intervention in under an hour experinced benefit compared to 23.3% (1-24h) and 13.3% (over 24 hours later), with the early intervention outperfoming the latter two groups on auditory tests. This study investigated Piracetam as the pathology of AAT involves hypoxia in the cochlea, which Piracetam is though to preserve.
Inhibition of steroid synthesis in general and an adrenalectomy (removal of the adrenal glands) appears to abolish the memory-enhancing effects of Piracetam and this learning inhibition is fully reversed when optimal circulating levels of corticosterone (3ug/mL) and aldosterone (30ng/mL) are maintained; suggesting their importance in the signalling of Piracetam.
Partial restoration of effects are noted with either aldosterone or corticosterone, both of which signal through the mineralocorticoid type I receptor (as blocking with epoxymexrenon abolishes the effects of Piracetam regardless of serum hormone levels) which also appears to exist when the glucocorticoid receptor is selectively blocked. and the interactions of Racetam compounds and corticosteroids appear to follow a U curve, with higher doses of cortisol attenuating the benefits of Piracetam, with 30-100mg/kg Corticosterone in otherwise normal mice abolishing the effects of Piracetam with no apparent inhibition at 3mg/kg; same effects were noted with supraphysiological levels of 100-300mcg/kg aldosterone.
One study in chicks that injected Piracetam noted an increase in corticosterone, where a 50mg/kg injection increased corticosterone levels 24.9% after training.
Corticosteroids and Aldosterone are critical for the memory enhancing effects of Piracetam, probably via the Mineralocorticoid Type I receptor; excessive levels of either hormone abolish the benefits in a similar manner as does no circulating levels
Racetam compounds are typically supplemented alongside cholinergic compounds as their mechanisms are highly interrelated. Administration of Piracetam causes a decrease in acetylcholine levels in the hippocampus with unknown mechanisms.
In a few animal models, choline supplementation has been noted to increase the memory and cognitive effects of Piracetam when coingested. These effects seem to be greatest in models of slight cognitive impairment, such as aging.
These studies on Piracetam and choline synergism have not been tested in humans.
May augment the relatively poor memory enhancing effects of Piracetam in otherwise healthy animals, but administration of choline alongside Piracetam is not a prerequisite to its efficacy and has not been tested in humans
Chronic alcohol consumption is related to build-up of lipofuscin in brain tissue of which piracetam has been implicated in reversing (both in rats) after cessation of alcohol and treatment of piracetam. Piracetam is also implicated in increasing synaptic reorganization and alleviating further loss of neurons after alcoholism.
May attenuate some pathology associated with excessive alcohol consumption (alcoholism)
Cinnarizine is an anti-histamine used for motion sickness and that is sometimes combined with Piracetam as a combination product called Fezam (Phezam) or Omaron. It is touted that the ingredients are synergistic with each other in regards to increasing cerebral oxygenation, although the synergism has not been shown experimentally. Both compounds in isolation are effective at preventing hypoxia-related damages however.
Said to be synergistic, this has not yet been demonstrated
Morin is a flavonoid compound found in Maclura pomifera (Osage Orange), tinctoria (Old Fustic), Morus Alba, and Psidium guajava (Guava) that serves as an inhibitor of CYP3A4 and P-Gyp. A 10mg/kg Morin pretreatment for a period of 7 days in rats was able to increase the AUC of a 50mg/kg Piracetam dose 1.5 and increase its Cmax by 1.45, but acute Morin ingestion failed to mimic these results. The authors suggested that a Morin-rich diet could influence pharmacokinetics of Piracetam.
May increase apparent bioavailability when measured in serum due to enzyme inhibition
Due to Piracetam being the atypical memory enhancing standard, it is sometimes used as an active control for other compounds to assess memory enhancing effects of those other compounds; this section compiles those studies
Asparagus Racemosus at oral doses of 50, 100, and 200mg/kg (an extract concentrated for 62.2% saponins) was not significantly different than 500mg/kg Piracetam in improving spatial memory; no dose-dependence was seen despite the acetylcholinesterase properties of Asparagus Racemosus being dose-dependent.
100mg/kg Clitorea Ternatea water extract is not significantly different than 50mg/kg Piracetam in memory retention and spatial learning when measured after 9 days, although Piracetam outperformed Clitoria after the first day.
Adverse effects, although rare and of short duration are limited to anxiety, insomnia, drowsiness and agitation. It may be safe for up to 18 months in humans at doses of 3.2g daily with one year-long study in ambulatory patients with Alzheimer's using 8g daily reporting no side effects. Piracetam also appears to have clinical usage (and a lack of side effects) when used in youth for the purpose of Breath Holding Spells at oral doses of 50-100mg/kg bodyweight in children aged 5-60 months.
Piracetam appears to be quite non-toxic at common doses used, and a few studies exceeding recommended dose (4.8g daily) fail to find toxicity associated with Piracetam
In general, racetams (usually referring to Class I racetams; Pi-, Ani-, and Oxi-) are said to have little side effects and low toxicity rates at commonly used dosages and up to 12g for up to 8 weeks. However, a possibility for adverse drug-drug interactions persists for Piracetam due to it interacting with blood in an anti-clotting manner (and such, caution should be taken when pairing Piracetam with pharmaceutical blood thinning agents such as Warfarin or potent nutraceutical options).
- The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients.
- A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder.
- Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. (2010)
- Gualtieri F, et al. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des. (2002)
- Dimond SJ, et al. Some effects of piracetam (UCB 6215, Nootropyl) on chronic schizophrenia. Psychopharmacology (Berl). (1979)
- Giurgea C. The "nootropic" approach to the pharmacology of the integrative activity of the brain. Cond Reflex. (1973)
- Tilborg A, et al. Structural study of piracetam polymorphs and cocrystals: crystallography redetermination and quantum mechanics calculations. Acta Crystallogr B. (2011)
- Renal handling of drugs in the healthy elderly.
- Tacconi MT, Wurtman RJ. Piracetam: physiological disposition and mechanism of action. Adv Neurol. (1986)
- Rameis H, et al. Pharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal elimination. Int J Clin Pharmacol Ther. (1994)
- Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine.
- Domańska-Janik K, Zaleska M. The action of piracetam on 14C-glucose metabolism in normal and posthypoxic rat cerebral cortex slices. Pol J Pharmacol Pharm. (1977)
- Grau M, Montero JL, Balasch J. Effect of Piracetam on electrocorticogram and local cerebral glucose utilization in the rat. Gen Pharmacol. (1987)
- Heiss WD, et al. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Flow Metab. (1988)
- Naftalin RJ, Cunningham P, Afzal-Ahmed I. Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport. Br J Pharmacol. (2004)
- Keil U, et al. Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol. (2006)
- Copani A, et al. Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. J Neurochem. (1992)
- Cohen SA, Müller WE. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology. (1993)
- Pilch H, Müller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology (Berl). (1988)
- Ahmed AH, Oswald RE. Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem. (2010)
- Solntseva EI, et al. The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen Pharmacol. (1997)
- Bravo-Martínez J, et al. A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons. Exp Biol Med (Maywood). (2012)
- Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. (2002)
- Winnicka K, Tomasiak M, Bielawska A. Piracetam--an old drug with novel properties?. Acta Pol Pharm. (2005)
- Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev. (1994)
- Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. (2005)
- Müller WE, et al. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol. (1997)
- Eckert GP, Cairns NJ, Müller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J Neural Transm. (1999)
- Peuvot J, et al. Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol. (1995)
- Müller WE, et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. Mol Neurobiol. (2010)
- Leuner K, et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease. Antioxid Redox Signal. (2007)
- Leuner K, et al. Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam. Front Neurosci. (2010)
- Maillis A, et al. Effects of piracetam on single central neurons. Neuropsychobiology. (1988)
- Dimond SJ, Brouwers EM. Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology (Berl). (1976)
- Wilsher C, Atkins G, Manfield P. Piracetam as an aid to learning in dyslexia. Preliminary report. Psychopharmacology (Berl). (1979)
- Mindus P, et al. Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand. (1976)
- Waegemans T, et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord. (2002)
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. (2001)
- Israel L, et al. Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int Psychogeriatr. (1994)
- Chouinard G, et al. Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology (Berl). (1983)
- Stegink AJ. The clinical use of piracetam, a new nootropic drug. The treatment of symptoms of senile involution. Arzneimittelforschung. (1972)
- On the dose-effect relationship in the therapy with piracetam (author's transl).
- Abuzzahab FS Sr, et al. A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory. Pharmakopsychiatr Neuropsychopharmakol. (1977)
- Clinical experience with treatment by piracetam in gerontopsychiatry (author's transl).
- Croisile B, et al. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology. (1993)
- Batysheva TT, et al. Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders. Neurosci Behav Physiol. (2009)
- Sequelae of Closed Craniocerebral Trauma and the Efficacy of Piracetam in Its Treatment in Adolescents.
- Wilsher CR. Effects of piracetam on developmental dyslexia. Int J Psychophysiol. (1986)
- Fedi M, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol. (2001)
- Libov I, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. (2007)
- Uebelhack R, et al. Effect of piracetam on cognitive performance in patients undergoing bypass surgery. Pharmacopsychiatry. (2003)
- Holinski S, et al. Cerebroprotective effect of piracetam in patients undergoing coronary bypass burgery. Med Sci Monit. (2008)
- Holinski S, et al. Cerebroprotective effect of piracetam in patients undergoing open heart surgery. Ann Thorac Cardiovasc Surg. (2011)
- Szalma I, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg. (2006)
- Ricci S, et al. Piracetam in acute stroke: a systematic review. J Neurol. (2000)
- A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke.
- Güngör L, Terzi M, Onar MK. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases. Brain Lang. (2011)
- Kessler J, et al. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke. (2000)
- Szelies B, et al. Restitution of alpha-topography by piracetam in post-stroke aphasia. Int J Clin Pharmacol Ther. (2001)
- Kampman K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav. (2003)
- Navarro SA, et al. Analgesic activity of piracetam: effect on cytokine production and oxidative stress. Pharmacol Biochem Behav. (2013)
- Mattie-Luksic M, Javornisky G, DiMario FJ. Assessment of stress in mothers of children with severe breath-holding spells. Pediatrics. (2000)
- DiMario FJ Jr. Breath-holding spells in childhood. Am J Dis Child. (1992)
- Garg RK. Piracetam for the treatment of breath-holding spells. Indian Pediatr. (1998)
- Sawires H, Botrous O. Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells. Eur J Pediatr. (2012)
- Azam M, Bhatti N, Shahab N. Piracetam in severe breath holding spells. Int J Psychiatry Med. (2008)
- Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatr Neurol. (1998)
- Lukkarinen H, et al. Recurrent sinus arrest and asystole due to breath-holding spell in a toddler; recovery with levetiracetam-therapy. Circulation. (2010)
- Vural M, et al. High-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy. Mov Disord. (2003)
- IN-VIVO PLATELET INHIBITION BY PIRACETAM.
- Stockmans F, et al. Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb Haemost. (1998)
- Moriau M, et al. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung. (1993)
- Treatment of Acute Ischemic Stroke With Piracetam.
- Evers S, Grotemeyer KH. Piracetam and platelets--a review of laboratory and clinical data. Pharmacopsychiatry. (1999)
- Grotemeyer KH, et al. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci. (2000)
- Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res. (1991)
- Keeble JE, et al. Hydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanisms. Pain. (2009)
- Ndengele MM, et al. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB J. (2008)
- Wang ZQ, et al. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther. (2004)
- Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. (2010)
- Psillas G, et al. Potential efficacy of early treatment of acute acoustic trauma with steroids and piracetam after gunshot noise. Eur Arch Otorhinolaryngol. (2008)
- Lamm K, Arnold W. Successful treatment of noise-induced cochlear ischemia, hypoxia, and hearing loss. Ann N Y Acad Sci. (1999)
- Mondadori C, et al. Involvement of a steroidal component in the mechanism of action of piracetam-like nootropics. Brain Res. (1990)
- Mondadori C, Ducret T, Petschke F. Blockade of the nootropic action of piracetam-like nootropics by adrenalectomy: an effect of dosage. Behav Brain Res. (1989)
- Häusler A, et al. Adrenalectomy, corticosteroid replacement and their importance for drug-induced memory-enhancement in mice. J Steroid Biochem Mol Biol. (1992)
- Loscertales M, et al. Piracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid action. Eur J Neurosci. (1998)
- Mondadori C, Häusler A. Aldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetam. Brain Res. (1990)
- Mondadori C, Ducret T, Häusler A. Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics. Psychopharmacology (Berl). (1992)
- Mondadori C, Petschke F. Do piracetam-like compounds act centrally via peripheral mechanisms. Brain Res. (1987)
- Nootropic drugs and brain cholinergic mechanisms.
- Wurtman RJ, Magil SG, Reinstein DK. Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci. (1981)
- Pepeu G, et al. The relationship between the behavioral effects of cognition-enhancing drugs and brain acetylcholine. Nootropic drugs and brain acetylcholine. Pharmacopsychiatry. (1989)
- Fontani G, Grazzi F, Meucci M. Effect of piracetam plus choline treatment on hippocampal rhythmic slow activity (RSA) and behavior in rabbits. Life Sci. (1984)
- Platel A, et al. Habituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processes. Pharmacol Biochem Behav. (1984)
- Bartus RT, et al. Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging. (1981)
- Borges MM, Paula-Barbosa MM, Volk B. Chronic alcohol consumption induces lipofuscin deposition in the rat hippocampus. Neurobiol Aging. (1986)
- Brandão F, Paula-Barbosa MM, Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol. (1995)
- Brandão F, et al. Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Alcohol. (1996)
- Boĭko AN, et al. Phezam efficacy in patients with chronic cerebral ischemic disease. Zh Nevrol Psikhiatr Im S S Korsakova. (2005)
- Arabkhanova MA, et al. Phezam in combined therapy of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. (2008)
- Nikolova M, Nikolov R, Milanova D. Anti-hypoxic effect of piracetam and its interaction with prostacyclin. Methods Find Exp Clin Pharmacol. (1984)
- Nikolov R, Nikolova M, Milanova D. Study on the anti-hypoxic effect of cinnarizine and its interaction with prostacyclin. Methods Find Exp Clin Pharmacol. (1984)
- Sahu K, Shaharyar M, Siddiqui AA. Effect of Morin on pharmacokinetics of Piracetam in rats, in vitro enzyme kinetics and metabolic stability assay using rapid UPLC method. Drug Test Anal. (2012)
- Ojha R, et al. Asparagus recemosus enhances memory and protects against amnesia in rodent models. Brain Cogn. (2010)
- Rai KS, et al. Clitoria ternatea (Linn) root extract treatment during growth spurt period enhances learning and memory in rats. Indian J Physiol Pharmacol. (2001)
- Wattanathorn J, et al. Zingiber officinale Mitigates Brain Damage and Improves Memory Impairment in Focal Cerebral Ischemic Rat. Evid Based Complement Alternat Med. (2011)
- Piracetam - The original smart drug.
- Giurgea M. Piracetam: toxicity and reproduction studies. Farmaco Prat. (1977)
- De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam--its use in the treatment of acute stroke. Pharmacopsychiatry. (1999)
- Sinforiani E, et al. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. Int J Clin Pharmacol Res. (1990)